The antiviral drug tecovirimat (Tpoxx) is no better than placebo in achieving a shorter time to clinical resolution, reduced pain, or increased viral DNA clearance in adults infected with clade 2 mpox virus, per a phase 3 randomized controlled trial published yesterday in the New England Journal of Medicine.
An international roster of investigators in the Advancing Clinical Therapeutics Globally Study of Tecovirimat for Human Mpox Virus (STOMP/A5418) group randomly assigned 412 participants in a 2:1 ratio to receive either tecovirimat (275 patients) or a placebo (137) for 14 days from September 2022 to October 2024.
Clade 2 carries up to 7% fatality rate
Recent public health emergencies of international concern have been declared for both clade 2 mpox virus, which has caused more than 100,000 infections and 220…